Omeros (OMER) Income from Continuing Operations (2010 - 2026)
Omeros (OMER) reported Income from Continuing Operations of 51249000.0 for Q1 2026, up 236.43% on a YoY basis from 15233295.76 in Q1 2025, and up 239.68% sequentially from 36690000.0 in Q4 2025.
Omeros (OMER) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Income from Continuing Operations data on file, last reported at 51249000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 236.43% year-over-year to 51249000.0; the trailing twelve-month figure through Mar 2026 stood at 76847000.0 (up 61.02% YoY), and the FY2025 full-year result was 4808000.0, up 97.37% from the prior year.
- Income from Continuing Operations improved to 51249000.0 in Q1 2026, from 36690000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 51249000.0 in Q1 2026 to a low of 65125000.0 in Q2 2024.
- A 5-year average of 39655529.41 and a median of 43850000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 141.34% in 2022 and jumped 236.43% in 2026, its largest moves.
- Tracing OMER's Income from Continuing Operations over 5 years: stood at 26246000.0 in 2022, then slumped by 118.69% to 57398000.0 in 2023, then increased by 3.75% to 55244000.0 in 2024, then jumped by 33.59% to 36690000.0 in 2025, then soared by 239.68% to 51249000.0 in 2026.
- Business Quant data shows OMER's Income from Continuing Operations at 51249000.0 in Q1 2026, 36690000.0 in Q4 2025, and 47428000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | 51.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.25 Mn |
| Dec 31, 2025 | -36.69 Mn |
| Sep 30, 2025 | -47.43 Mn |
| Jun 30, 2025 | -43.98 Mn |
| Mar 31, 2025 | -37.57 Mn |
| Dec 31, 2024 | -55.24 Mn |
| Sep 30, 2024 | -39.23 Mn |
| Jun 30, 2024 | -65.13 Mn |
| Mar 31, 2024 | -43.85 Mn |
| Dec 31, 2023 | -57.40 Mn |
| Sep 30, 2023 | -51.66 Mn |
| Jun 30, 2023 | -44.29 Mn |
| Mar 31, 2023 | -39.68 Mn |
| Dec 31, 2022 | -26.25 Mn |
| Sep 30, 2022 | -54.79 Mn |
| Jun 30, 2022 | -41.70 Mn |
| Mar 31, 2022 | -40.52 Mn |
| Dec 31, 2021 | -105.16 Mn |
| Sep 30, 2021 | -22.70 Mn |
| Jun 30, 2021 | -79.34 Mn |